Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander E Perl

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Nature Medicine|September 27, 2024
Cytokine-mediated CAR T therapy resistance in AMLAnand S Bhagwat, Leonel Torres, Olga Shestova, et al.
Haematologica|April 21, 2019
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative studySabine Kayser, Robert K Hills, Marlise R Luskin, et al.
Nature Medicine|June 21, 2016
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemiaSheng Li, Francine E Garrett-Bakelman, Stephen S Chung, et al.
Blood|June 1, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapyVanessa E Kennedy, Cheryl A C Peretz, Anushka Walia, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood|May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyMartha L Arellano, Michael J Thirman, John F DiPersio, et al.
Blood Advances|July 1, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemiaMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>Mark J Levis, Mehdi Hamadani, Brent Logan, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Nature Medicine|September 27, 2024
Cytokine-mediated CAR T therapy resistance in AMLAnand S Bhagwat, Leonel Torres, Olga Shestova, et al.
Haematologica|April 21, 2019
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative studySabine Kayser, Robert K Hills, Marlise R Luskin, et al.
Nature Medicine|June 21, 2016
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemiaSheng Li, Francine E Garrett-Bakelman, Stephen S Chung, et al.
Blood|June 1, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapyVanessa E Kennedy, Cheryl A C Peretz, Anushka Walia, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood|May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyMartha L Arellano, Michael J Thirman, John F DiPersio, et al.
Blood Advances|July 1, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemiaMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>Mark J Levis, Mehdi Hamadani, Brent Logan, et al.
Pageof 9